Progesterone has been studied in 167 papers since 1997: 9 trials and 35 observational studies in people, 29 in animals, 5 in cells, 84 reviews; 69 in the past year. It is an approved medicine. The newest story, Oct 26, 2026: “Progesterone alleviates blood vessel aging in mice”.
Progesterone reduces vascular endothelial senescence in ovariectomized mice; human-cell studies report reduced senescence under D-galactose exposure but no clear effect with cigarette smoke extract. One group reports increased muscle protein synthesis in a trial in postmenopausal women. The papers include company-affiliated authors and a declaration of company ties.
59 findings in 42 papers from 2008 to 2026, 11 of them since May 2026
The findings reach people, from one lab or study. 25 independent labs in 15 countries; 149 trials, 6 about aging, 57 with no results posted.
“In postmenopausal women, both T and progesterone treatment increased the muscle protein fractional synthesis rate by approximately 50% (both P<.01)”
Cells, worms or flies, mice and humans: a single group.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
25 independent labs in 15 countries
1 finding against
149 trials, 6 about aging, 57 with no results posted
Funders: National Institutes of Health and others
3 of 45 findings with company ties
Human trial9
Humans35
Animals29
Cells5
In silico1
Studies in people
2 studies gave progesterone to people and measured what changed.
24 peopleWomenPostmenopausal women; treatment in postmenopausal women
The Journal of clinical endocrinology and metabolism, Dec 20, 2013
What did studies of progesterone find?
45
Studies of progesterone measured 45 outcomes; the most studied are oxidative stress and ROS signaling (3 studies), cellular senescence (2) and sleep disturbances (2).
Oxidative stress and ROS signaling
↓downin human cells1↓downin rats1↓downin yeast cells1
3 studies
Progesterone decreases oxidative stress and ROS signaling in human cells (D-galactose-induced senescence).
“In HAECs, P4 attenuated D-GAL–induced senescence and oxidative stress”
Progesterone decreases cellular senescence in mice (ovariectomized mice).
“P4 alleviates ovx-modelled postmenopausal acceleration of vascular endothelial ageing and dysfunction via PR-B–dependent transcriptional repression of KLHL38, thereby preserving SIRT1 protein stability and endothelial homeostasis.”
Animalsovariectomized micevascular endothelium4 or 8 mg/kg/day6 months
Progesterone decreases vasomotor symptoms in perimenopause and menopause.
“Progesterone therapy during perimenopause and menopause also indirectly leads to healthy ageing through effective treatment of night sweats, hot flushes, and disturbed sleep”
Progesterone prevents GFAP in MPTP-lesioned OVX mice.
“Striatal glial fibrillary acidic protein (GFAP), an astrogliosis marker, levels were elevated in MPTP-lesioned mice and this was similarly prevented with the hormonal treatment alone or in combination.”
Progesterone prevents dopamine loss in OVX MPTP-lesioned female mice.
“OVX MPTP-lesioned female mice showed a loss of striatal DA and metabolites content similarly prevented by treatments with raloxifene, progesterone and their combination.”
Progesterone decreases mammographic density increase in humans (combined with estrogen compared with estrogen-only hormone replacement therapy).
“Postmenopausal women treated with estrogen and progesterone regimens had a statistically significant lesser mammographic density increase than estrogen-only hormone replacement therapy regimens.”
Human trialcombined with estrogen compared with estrogen-only hormone replacement therapyestrogen plus progesterone regimenbreastfemales
Progesterone decreases brachial-ankle pulse wave velocity in humans (combined with percutaneous estradiol gel in postmenopausal grade 1 hypertension) (-0.6 ± 1.4 m/s).
“Within-group comparisons showed that EPT significantly decreased daytime heart rate and baPWV: the changes from baseline (mean ± standard deviation) were - 2.5 ± 5.7 bpm (P = 0.03) and - 0.6 ± 1.4 m/s (P = 0.04), respectively.”
Human trialcombined with percutaneous estradiol gel in postmenopausal grade 1 hypertensionmicronized100 mg/d12 weeksfemalesn = 17
Progesterone is associated with breast cancer in humans (compared with progestins; observational or case-control evidence).
“Micronised progesterone and dydrogesterone seem associated with a lower risk of breast cancer than progestins, as shown in observational or case-control studies”
Reviewcompared with progestins; observational or case-control evidencemicronizedfemales
bioRxiv : the preprint server for biology·Preprint
Breast cancer risk
↕mixedin humans1
1 study
Progesterone is associated with breast cancer risk in humans (Compared with progestin-based menopausal hormone therapy in postmenopausal women) (Similar or possibly better profile).
“P4- versus progestin-based MHT had a similar or possibly better profile for breast cancer and cardiovascular outcomes.”
ReviewCompared with progestin-based menopausal hormone therapy in postmenopausal womenfemales
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·
Core body temperature
↕mixedin mice1
1 study
Progesterone is associated with core body temperature in mice.
“These effects were only partially mimicked by hormonal replacement as Tc was affected by progesterone and to a lesser extent by estrogen but not by testosterone.”
A mouse study reports that progesterone prevents striatal dopamine loss in ovariectomized, MPTP-lesioned females. A preprint review describes inhibition of 5-alpha-reductase during the human menopausal transition.
Progesterone preserved half of the gene-activity response to estradiol, while bazedoxifene broadly suppressed estradiol-driven signaling in grafts of human uterine…Progesterone preserved half of the gene-activity response to estradiol, while bazedoxifene broadly suppressed estradiol-driven signaling in grafts of human uterine lining.
Mice with their ovaries removed that received daily progesterone for six months showed dose-dependent reversals of blood vessel cell aging, inflammation, and impaired…Mice with their ovaries removed that received daily progesterone for six months showed dose-dependent reversals of blood vessel cell aging, inflammation, and impaired relaxation.